← Leaderboards
Greg Bertenshaw
Biomarker Strategies, Llc
$5,801,048
Attributed
$5,801,048
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2013–19$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$5,801,048 · 5
By mechanism
N44$2,996,596 · 2
R44$2,282,049 · 1
R43$299,340 · 1
N43$223,063 · 1
Top collaborators
No co-investigators on record.
Most similar at Biomarker Strategies, Llc
Same institution · by research overlap
- Adam Schayowitz$1,230,745
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseTumorBiological MarkersSamplingDiagnostic TestsNeoplastic CellNon-Small-Cell Lung CarcinomaCancer DiagnosticsPharmaceutical PreparationsBiopsyCompanion DiagnosticsMolecularResistanceDiagnosisSolid NeoplasmCancer EtiologyEpidermal Growth Factor ReceptorOncogenicCollectionInstrumentCellsClinically ActionableMalignant Neoplasm Of LungCell Line
Grant awards (7)
SBIR Topic 354: A Novel Predictive Test for Response to Combination Immunotherapies for Patients with non-small cell lung cancer (NSCLC)$1,498,027
N44 · FY2019 · CA · contact PI
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$993,966
R44 · FY2018 · CA · contact PI
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$988,207
R44 · FY2017 · CA · contact PI
Development of a companion diagnostic to predict response to cetuximab in patients with head and neck squamous cell carcinoma$299,340
R43 · FY2017 · CA · contact PI
IGF::OT::IGF SBIR PHASE I TOPIC 354-A NOVEL PREDICTIVE TEST FOR RESPONSE TO IMMUNOTHERAPIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER; POP 09/19/16-06/18/17$223,063
N43 · FY2016 · CA · contact PI
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$299,876
R44 · FY2015 · CA · contact PI
A Functional Companion Diagnostic Test to Predict Optimal Therapy for Melanoma$1,498,569
N44 · FY2013 · CA · contact PI